De Novo in double collaboration
De Novo Pharmaceuticals has entered into collaborative agreements with ChemOvation and Argenta Discovery. ChemOvation will provide synthetic chemistry services and expertise for the generation of low molecular weight drug-like compounds arising from De Novo's proprietary computational modelling for a number of targets currently within De Novo's discovery portfolio.
Dr Alan Stuttle, ceo of ChemOvation, commented: 'We are delighted at having been chosen to support De Novo in its quest for novel drug entities arising from its proprietary computational software. We look forward to a fruitful collaboration with De Novo in supporting the development of its drug candidates.'
Argenta Discovery will also provide De Novo with synthetic chemistry and screening services for the generation and testing of low molecular weight, drug-like compounds whose design has been driven by De Novo's proprietary computational modelling.
Dr Tony Baxter, ceo of Argenta, said: 'I am delighted that De Novo has selected Argenta as a partner for this part of its expanding drug discovery plans. I think the synergies between us will help us to obtain good results quickly and so move De Novo's discovery programme forward rapidly.'
Dr David Bailey, ceo of De Novo, added, 'By employing its proprietary design algorithms, De Novo's discovery portfolio is moving rapidly to meet the urgent need for high quality lead candidates in key therapeutic areas.'